Colistin monotherapy versus colistin plus sitafloxacin for therapy of carbapenem-resistant acinetobacter baumannii infections: a preliminary study

HIGHLIGHTS

  • who: Rujipas Sirijatuphat et al. from the Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand have published the research work: Colistin Monotherapy versus Colistin plus Sitafloxacin for Therapy of Carbapenem-Resistant Acinetobacter baumannii Infections: A Preliminary Study, in the Journal: Antibiotics 2022, 11, 1707. of /2022/
  • what: The in vitro study of sitafloxacin against carbapenem-resistant (CR) demonstrated activity against most strains of CR A. and the combination of and sitafloxacin showed an in vitro synergistic effect against CR A. This study aimed to compare efficacy and safety between plus sitafloxacin . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?